Anxiety News and Research

Latest Anxiety News and Research

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

21 Dec 2009

CIGNA suggests the 'To Do' list to stay healthy during this holiday season

‘Tis the season for celebrating with family and friends -- and searching for those perfect gifts. CIGNA suggests adding another item to the top of the holiday “To Do” list: Be sure to take needed medications to stay healthy this holiday season and into the New Year.

19 Dec 2009

Study provides new definition on dyslexia

Contrary to popular belief, some very smart, accomplished people cannot read well. This unexpected difficulty in reading in relation to intelligence, education and professional status is called dyslexia, and researchers at Yale School of Medicine and University of California Davis, have presented new data that explain how otherwise bright and intelligent people struggle to read.

18 Dec 2009

A program to reduce depression and isolation among the elderly during holiday season

MyWay Village, the first senior-focused technology company to help seniors get online in an easy and social way by combining access to simplified technology with personal training and support, today announced that their Connected Living program is reducing depression and feelings of isolation especially during the holiday season within senior communities where the company's programs are being offered.

18 Dec 2009

Cannabis can cause depression and anxiety in teenagers

Canadian teenagers are among the largest consumers of cannabis worldwide. The damaging effects of this illicit drug on young brains are worse than originally thought, according to new research by Dr. Gabriella Gobbi, a psychiatric researcher from the Research Institute of the McGill University Health Centre. The new study, published in Neurobiology of Disease, suggests that daily consumption of cannabis in teens can cause depression and anxiety, and have an irreversible long-term effect on the brain.

18 Dec 2009

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

18 Dec 2009

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.

17 Dec 2009

ASA offers practical ways for sufferers to take active role in treatment of pain

Whether the result of injury, illness or a chronic condition, 70 million Americans experience pain annually. The individual pain sufferer may experience a diminished quality of life, lack of mobility and added stress.

17 Dec 2009

Professional treatment can benefit first responders to cope with emotional challenges

Professional first responders are prepared, equipped and trained to handle various emergency situations, from car accidents to terrorist attacks and other major disasters. Today, however, this great responsibility can be particularly burdensome on one's emotions.

17 Dec 2009

ARNMD meeting examines psychological and neurological aspects of PTSDs and traumatic brain injuries

War is hell, as the old saying goes -- with loss of life and limb, destruction of infrastructure and the environment, and devastating costs. Recent biomedical research has shed light on another pernicious consequence of military conflict: psychological and neurological conditions like post-traumatic stress disorder and traumatic brain injury. At the same time, researchers have worked to uncover some of the motives and meanings of war.

17 Dec 2009

CIHR experts offer suggestions for stress-free holiday

The holiday season is synonymous with joy, family and sharing, but it can also mean anxiety, melancholy and illness. With the recent economic downturn and the H1N1 pandemic, many Canadians are facing higher stress levels, sleepless nights and health problems.

17 Dec 2009

Flowers can uplift patients’ mood and reduce pain and anxiety

Does flower water harbour potentially deadly bacteria? Do bedside blooms compete with patients for oxygen? Do bouquets pose a health and safety risk around medical equipment?

17 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

A new study links chronic obstructive pulmonary disease, or COPD, with increased activity of cells that act as sentinels to activate the body's immune system.

15 Dec 2009

Risks and benefits of CT scans

Doses of radiation from commonly performed computed tomography (CT) scans vary widely, appear higher than generally believed and may contribute to an estimated tens of thousands of future cancer cases, according to two reports in the December 14/28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Dec 2009

Antidepressant and anti-anxiety medications linked to increased risk of cardiovascular events and death

Women with suspected coronary artery disease (CAD) who report taking antidepressant and anti-anxiety medications have an increased risk of cardiovascular events, including heart attacks and strokes, and death compared to women not taking these medications, according to researchers at the Uniformed Services University of the Health Sciences (USU).

15 Dec 2009

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.

15 Dec 2009

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

Recipients of ‘2009 Putting Patients First grant’ program announced

Recognizing the need for programs that improve patient safety and quality care, AHRA: The Association for Medical Imaging Management and Toshiba America Medical Systems, Inc. announced the six recipients of the second annual Putting Patients First grant program.

14 Dec 2009

Cultural activities may improve health and protect against depression

If you paint, dance or play a musical instrument - or just enjoy going to the theatre or to concerts -- it's likely that you feel healthier and are less depressed than people who don't, a survey of nearly 50,000 individuals from all socio-economic backgrounds from a county in mid-Norway shows.

14 Dec 2009

Anxiety News and Research

Latest Anxiety News and Research

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

CIGNA suggests the 'To Do' list to stay healthy during this holiday season

Study provides new definition on dyslexia

A program to reduce depression and isolation among the elderly during holiday season

Cannabis can cause depression and anxiety in teenagers

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

ASA offers practical ways for sufferers to take active role in treatment of pain

Professional treatment can benefit first responders to cope with emotional challenges

ARNMD meeting examines psychological and neurological aspects of PTSDs and traumatic brain injuries

CIHR experts offer suggestions for stress-free holiday

Flowers can uplift patients’ mood and reduce pain and anxiety

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

Risks and benefits of CT scans

Antidepressant and anti-anxiety medications linked to increased risk of cardiovascular events and death

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

ZYPREXA RELPREVV approved by FDA

Recipients of ‘2009 Putting Patients First grant’ program announced

Cultural activities may improve health and protect against depression

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Anxiety News and Research

Latest Anxiety News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in